T153. Wearable inertial sensors produce reliable endpoints in healthy volunteers and detect levodopa -induced changes in Parkinson's disease patients. (May 2018)

• Record Type: Journal Article
• Authors: Ramos, Vesper; Naylor, Melissa; Demanuele, Charmaine; Zhang, Hao; Amato, Stephen; Wacnik, Paul; Hameed, Farhan; Anand, Vibha; Bilal, Erhan; Kangarloo, Tairmae; Ho, Bryan; Bergethon, Peter; Erb, Kelley; Karlin, Dan
• Is Part Of: Clinical neurophysiology. Volume 129(2018)Supplement 1
• Page Start: e61
• Publication Date: 2018-05
• Subjects: Neurophysiology -- Periodicals; Electroencephalography -- Periodicals; Electromyography -- Periodicals; Neurology -- Periodicals; 612.8
• DOI: 10.1016/j.clinph.2018.04.154
• Languages: English
• ISSNs: 1388-2457

Abstract

Abstract : Introduction: Objective monitoring of movement in Parkinson's Disease (PD) is important to assess response to treatment. Currently, PD treatment decisions are made based on expert assessment and conduct of clinical rating scales and patient diaries. Each of these is insensitive, episodic and subjective with inherent rater bias. Wearable inertial sensor technology using accelerometers and gyroscopes, which can quantify gait metrics, have been studied for their ability to monitor PD signs. We sought to evaluate the performance of wearable inertial sensor technology in quantifying movement related to PD signs using the Mobility Lab system (http://www.apdm.com ). Methods: We compared endpoints of the Mobility Lab 2-min walk test in 41 healthy volunteers (HV) and in 25 PD patients. HV had two test sessions at greater than a one hour interval. Each PD patient also performed the task twice: once in ON state ( ∼ 1 h after administering the patient's scheduled levodopa dose) and again in the OFF state (immediately prior to administering the patient's next scheduled levodopa dose). PD patients were randomized with half performing on state evaluations prior to off state evaluations, and the other half reversing this order. Each subject walked 10 meter linear laps with a 180 degree turn at the apex for two minutes while wearing sensors on each limb, and the sternum and lumbar regions. Results: We found the highest reliability of the following endpoints in HV: cadence (Pearson's r = 0.9860), stride length ( r = 0.963), and arm range of motion ( r = 0.962). In PD patients, Mobility Lab endpoints including turn duration ( p = 0.003), gait speed ( p = 0.009), stride length ( p = 0.006) and arm range of motion ( p = 0.02) significantly differed before and after levodopa intake, and correlated with the Unified Parkinson Disease Rating Scale Motor Score (e.g. turn duration r = 0.4). Conclusion: The Mobility Lab System 2-min walk test generated endpoints with good reliability and detected changes in PD patients before and after levodopa. Wearable inertial sensors have the potential to enhance our ability to detect signals of efficacy in therapeutic development.